Elderly breast cancer patients treated with Nab-paclitaxel: Results in real clinical practice

Clinical trials have shown that Nab-paclitaxel is more effective than paclitaxel in the treatment of metastatic breast cancer (MBC). Although the incidence of cancer increases with age, elderly patients are under-represented in clinical trials and tend to receive suboptimal treatment to avoid toxici...

Full description

Saved in:
Bibliographic Details
Published in:Revista de senología y patología mamaria 2021-04, Vol.34 (2), p.93-99
Main Authors: Gascón Ruiz, Marta, Casas Deza, Diego, Lafuente Blasco, Miguel, Sesma Goñi, Andrea, Cruellas Lapeña, Mara, Alonso Martín, Natalia, Zapata García, María, Ocáriz Diez, Maitane, Zurera Berjaga, María, Quilez Bielsa, Elisa, Murillo Jaso, Laura, Andrés Conejero, Raquel
Format: Article
Language:English
Subjects:
Elderly patients
Nab-paclitaxel
Pacientes ancianos
Práctica clínica real
Real-world clinical practice
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trials have shown that Nab-paclitaxel is more effective than paclitaxel in the treatment of metastatic breast cancer (MBC). Although the incidence of cancer increases with age, elderly patients are under-represented in clinical trials and tend to receive suboptimal treatment to avoid toxicity. The main aim of our study was to compare progression-free survival (PFS) among patients older and younger than 65 years treated with Nab-paclitaxel in real-world clinical practice. A secondary aim was to assess overall survival (OS) as well as the response rate and toxicity. This single-centre study retrospectively analyzed a cohort of 60 patients with MBC treated with Nab-paclitaxel monotherapy in Hospital Clínico Lozano Blesa de Zaragoza. The median PFS was 5.92 months (3.62–11.2) in patients
ISSN:0214-1582
DOI:10.1016/j.senol.2020.06.006